4//SEC Filing
Hall Steven Edward 4
Accession 0000899243-20-023369
CIK 0001815442other
Filed
Aug 24, 8:00 PM ET
Accepted
Aug 25, 4:30 PM ET
Size
10.5 KB
Accession
0000899243-20-023369
Insider Transaction Report
Form 4
Hall Steven Edward
Director
Transactions
- Conversion
Common Stock
2020-08-25+2,192,249→ 2,192,249 total(indirect: See Footnote) - Conversion
Series A Convertible Preferred Stock
2020-08-25−2,511,198→ 0 total(indirect: See Footnote)→ Common Stock (1,574,517 underlying) - Conversion
Series B Convertible Preferred Stock
2020-08-25−985,220→ 0 total(indirect: See Footnote)→ Common Stock (617,732 underlying)
Footnotes (3)
- [F1]Represents the total number of shares of common stock received upon the conversion of the Issuer's preferred stock in connection with the closing of the Issuer's initial public offering.
- [F2]All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- [F3]These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001602732
Filing Metadata
- Form type
- 4
- Filed
- Aug 24, 8:00 PM ET
- Accepted
- Aug 25, 4:30 PM ET
- Size
- 10.5 KB